Drug Trial Radar · NCT06020560
Study of Low Molecular Weight Heparins
Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
65,000
Planned (sponsor's estimate)
Start
Mar 23, 2023
Primary completion
Mar 23, 2025
Study completion Mar 23, 2025
Sponsor
- Lead sponsor
- Herlev HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.
Conditions
- Anticoagulant
- Venous Thromboembolism
- Prophylaxis
- Treatment
Interventions
Dalteparin Prefilled SyringeDrug
Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
Tinzaparin profiled syringeDrug
Patients will via a software module (Through a patient journal system) be allocated to either dalteparin or tinzaparin. Clusters are timeframes of 1 hour.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30-day all-cause mortality and bleeding requiring blood transfusionTime frame: 30 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Amager-Hvidovre Hospital
Copenhagen, Denmark · Recruiting
Frederiksberg and Bispebjerg Hospital
Copenhagen, Denmark · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Herlev and Gentofte Hospital
Herlev, Denmark · Recruiting
Nordsjællands Hospital
Hillerød, Denmark · Recruiting
Næstved, Ringsted, Slagelse Hospital
Næstved, Denmark · Recruiting
Nykøbing Falster Hospital
Nykøbing Falster, Denmark · Recruiting
Bornholm Hospital
Rønne, Denmark · Recruiting
Roskilde, Køge Hospital
Roskilde, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.